Matches in SemOpenAlex for { <https://semopenalex.org/work/W202187616> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W202187616 endingPage "8" @default.
- W202187616 startingPage "83" @default.
- W202187616 abstract "To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.Published articles, abstracts, and conference proceedings.Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU. Diagnosis of DPD deficiency must be confirmed by specialized laboratory tests. The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.Early recognition of this serious pharmacogenetic syndrome may allow for the modification of future chemotherapy, thus avoiding further life-threatening toxicities.Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care." @default.
- W202187616 created "2016-06-24" @default.
- W202187616 creator A5006865258 @default.
- W202187616 creator A5010066530 @default.
- W202187616 creator A5045704757 @default.
- W202187616 creator A5077563999 @default.
- W202187616 creator A5081635737 @default.
- W202187616 date "1997-01-01" @default.
- W202187616 modified "2023-09-23" @default.
- W202187616 title "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy." @default.
- W202187616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9007910" @default.
- W202187616 hasPublicationYear "1997" @default.
- W202187616 type Work @default.
- W202187616 sameAs 202187616 @default.
- W202187616 citedByCount "13" @default.
- W202187616 countsByYear W2021876162012 @default.
- W202187616 countsByYear W2021876162022 @default.
- W202187616 crossrefType "journal-article" @default.
- W202187616 hasAuthorship W202187616A5006865258 @default.
- W202187616 hasAuthorship W202187616A5010066530 @default.
- W202187616 hasAuthorship W202187616A5045704757 @default.
- W202187616 hasAuthorship W202187616A5077563999 @default.
- W202187616 hasAuthorship W202187616A5081635737 @default.
- W202187616 hasConcept C104317684 @default.
- W202187616 hasConcept C123321153 @default.
- W202187616 hasConcept C126322002 @default.
- W202187616 hasConcept C135763542 @default.
- W202187616 hasConcept C143998085 @default.
- W202187616 hasConcept C177713679 @default.
- W202187616 hasConcept C185592680 @default.
- W202187616 hasConcept C197934379 @default.
- W202187616 hasConcept C2776694085 @default.
- W202187616 hasConcept C2778050828 @default.
- W202187616 hasConcept C2778496288 @default.
- W202187616 hasConcept C2779802037 @default.
- W202187616 hasConcept C2780456651 @default.
- W202187616 hasConcept C55493867 @default.
- W202187616 hasConcept C55775858 @default.
- W202187616 hasConcept C71924100 @default.
- W202187616 hasConceptScore W202187616C104317684 @default.
- W202187616 hasConceptScore W202187616C123321153 @default.
- W202187616 hasConceptScore W202187616C126322002 @default.
- W202187616 hasConceptScore W202187616C135763542 @default.
- W202187616 hasConceptScore W202187616C143998085 @default.
- W202187616 hasConceptScore W202187616C177713679 @default.
- W202187616 hasConceptScore W202187616C185592680 @default.
- W202187616 hasConceptScore W202187616C197934379 @default.
- W202187616 hasConceptScore W202187616C2776694085 @default.
- W202187616 hasConceptScore W202187616C2778050828 @default.
- W202187616 hasConceptScore W202187616C2778496288 @default.
- W202187616 hasConceptScore W202187616C2779802037 @default.
- W202187616 hasConceptScore W202187616C2780456651 @default.
- W202187616 hasConceptScore W202187616C55493867 @default.
- W202187616 hasConceptScore W202187616C55775858 @default.
- W202187616 hasConceptScore W202187616C71924100 @default.
- W202187616 hasIssue "1" @default.
- W202187616 hasLocation W2021876161 @default.
- W202187616 hasOpenAccess W202187616 @default.
- W202187616 hasPrimaryLocation W2021876161 @default.
- W202187616 hasRelatedWork W1541193958 @default.
- W202187616 hasRelatedWork W2002243859 @default.
- W202187616 hasRelatedWork W2033096478 @default.
- W202187616 hasRelatedWork W2044708275 @default.
- W202187616 hasRelatedWork W2174409359 @default.
- W202187616 hasRelatedWork W2353934352 @default.
- W202187616 hasRelatedWork W2374339158 @default.
- W202187616 hasRelatedWork W2392222733 @default.
- W202187616 hasRelatedWork W2465463735 @default.
- W202187616 hasRelatedWork W2592570503 @default.
- W202187616 hasVolume "24" @default.
- W202187616 isParatext "false" @default.
- W202187616 isRetracted "false" @default.
- W202187616 magId "202187616" @default.
- W202187616 workType "article" @default.